Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Ledda

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myelomaMattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Blood|July 25, 2008
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosisSyed Khizer Hasan, Ashley N Mays, Tiziana Ottone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myelomaMattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Blood|July 25, 2008
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosisSyed Khizer Hasan, Ashley N Mays, Tiziana Ottone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Pageof 3